Drugs / GS-4774
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01779505 | Jan → Aug 2013 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02174276 | Jul 2014 → Feb 2016 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01943799 | Sep 2013 → Sep 2014 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-4774 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02174276 ↗ |
| Modality | Vaccine | “GS-4774, a hepatitis B virus-specific therapeutic vaccine” PMID 25045824 ↗ Jul 2014 |
| Route | Subcutaneous | “five subcutaneous injections at weekly intervals with one monthly booster” PMID 25045824 ↗ Jul 2014 |